TWST (Twist Bioscience Corporation) PDUFA Date | FDA Catalyst & Approval Status

Jul 15, 2026

Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026

Twist Bioscience Corporation will release its financial results for the fiscal 2026 third quarter on August 3, 2026. The results will cover the period ending June 30, 2026, and will be announced before the market opens. Following the announcement, the company will host a conference call and live audio webcast to discuss the results and provide a business update.

May 27, 2026

Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

Twist Bioscience is scheduled to present at the William Blair 46th Annual Growth Stock Conference. Details regarding the presentation content or specific topics have not been disclosed in the article.

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

Twist Bioscience has announced its financial results for the second quarter of fiscal 2026. The report includes key financial metrics and performance indicators, although specific details on revenue or growth were not disclosed in the provided text. The announcement is part of the company's ongoing financial reporting.

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience has expanded its clonal genes offering to include long and complex sequences. This move aims to enhance their product portfolio and cater to a broader range of applications in synthetic biology. The expansion reflects the company's commitment to innovation and meeting customer needs in the biopharma sector.

Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results - Record revenue of $110.7 million in 2QFY26 Increase of more than 19% over $92.8 million in 2QFY25 13th consecutive quarter of sequential growth - -

Twist Bioscience Corporation reported its fiscal second quarter 2026 financial results, showcasing a record revenue of $110.7 million, reflecting a 19% increase compared to the same quarter last year. This quarter marks the thirteenth consecutive quarter of growth for the company, with improved gross margins. Despite the positive financial results, the company reported a net loss of $44.0 million and an increase in selling, general and administrative expenses. Looking forward, Twist has raised its revenue guidance for fiscal 2026 and anticipates achieving adjusted EBITDA breakeven by the fourth quarter.

Apr 21, 2026

Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

Twist Bioscience Corporation will announce its fiscal 2026 second quarter financial results on May 4, 2026, before market opening. A conference call will follow at 8:00 a.m. ET for discussion and updates. Additionally, an Investor Day is scheduled for May 21, 2026, featuring a facility tour and presentations from senior leaders.

Feb 18, 2026

Twist Bioscience to Present at Upcoming Investor Conferences

Twist Bioscience Corporation announced that its CEO, Dr. Emily M. Leproust, and CFO, Adam Laponis, will participate in upcoming investor conferences through fireside chats. These events will be webcast live and available for replay for 30 days. The company emphasizes its role in supporting customers across various industries with its advanced DNA synthesis technology.

Feb 17, 2026

▲ +7.7%on this newsshared move

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

Twist Bioscience has entered a licensing agreement with Invenra to co-exclusively provide the B-Body bispecific antibody platform. This partnership aims to enhance Twist's antibody discovery services and meet the increasing demand for bispecific therapeutics. The deal includes a $5 million upfront payment and a 6% ownership stake in Invenra. Twist's CEO emphasizes the potential of bispecific antibodies in addressing unmet medical needs.

Feb 10, 2026

Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

Twist Bioscience has launched two next-generation library preparation kits, the Twist TrueAmp and the Twist PCR-Free WGS Library Preparation Kits. These kits are designed to enhance sequencing accuracy and efficiency, particularly for low-input and difficult sample types. The TrueAmp polymerase and engineered ligase improve performance and reduce errors, catering to various clinical research applications.

Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

Twist Bioscience Corporation announced its financial results for the first quarter of fiscal 2026, ending December 31, 2025. The company highlighted its innovative DNA synthesis platform, which supports advancements in medicine, agriculture, and other sectors. A conference call is scheduled to discuss these results and company updates.

Feb 2, 2026

▲ +14%on this newsshared move

Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results - Record revenue of $103.7 million in 1QFY26 Increase of 17% over $88.7 million in 1QFY25 12th consecutive quarter of sequential growth - - Gross margi

Twist Bioscience reported financial results for the first quarter of fiscal 2026, showcasing record revenue of $103.7 million, a 17% increase from the same quarter last year. The company achieved a gross margin of 52.0%, marking an improvement over the previous year, and raised its full-year revenue guidance to between $435 million and $440 million. Despite these positives, the company posted a net loss of $30.5 million and continued to operate at a loss in adjusted EBITDA, though this figure improved from the prior year’s loss. Twist remains focused on maintaining revenue growth while aiming for profitability.

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

Twist Bioscience has launched new research-grade plasmid DNA preps aimed at enhancing pre-clinical studies for pharmaceutical and biotech clients. These preps are designed to meet specific quality requirements, including being animal origin-free and endotoxin-free. The new offerings aim to streamline supply chains and support the development of nucleic acid therapeutics.

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2025 Financial Results - Record revenue of $376.6 million in Fiscal 2025 Increase of 20% over $313.0 million in Fiscal 2024 - - Record revenue of $99.0

Twist Bioscience Corporation reported strong financial results for the fourth quarter and full year of fiscal 2025, achieving record revenues of $376.6 million, a 20% increase from fiscal 2024. The company's gross margin improved to 50.7%, and it recorded an adjusted EBITDA loss of $(46.9) million, showing signs of financial stability. The CEO highlighted continuing growth as Twist enters fiscal 2026, with expectations to maintain high gross margins and ultimately reach adjusted EBITDA breakeven. Despite a significant net loss of $77.7 million, overall performance positions the company for future success.

Document Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors SOUTH SAN FRANCISCO, Calif.

Twist Bioscience has appointed Trynka Shineman Blake to its board of directors, enhancing the company's leadership team. Shineman Blake, former CEO of Vistaprint, brings nearly thirty years of experience in corporate governance and digital transformation. She is expected to contribute to Twist's strategic direction during a pivotal growth phase as the company aims for adjusted EBITDA breakeven. Her appointment is seen as a way to further advance Twist's customer-focused initiatives and optimize product development.

Aug 4, 2025

▼ -10.3%on this news· ran to -26% by day 3shared move

Twist Bioscience Reports Fiscal Third Quarter 2025 Financial Results - Record revenue of $96.1 million in 3QFY25 Increase of 18% over $81.5 million in 3QFY24, 10th consecutive quarter of sequential growth - - Gross margi

Twist Bioscience has reported strong financial results for the third quarter of fiscal 2025, with record revenues of $96.1 million, marking an 18% year-over-year increase. The company also saw improvements in gross margin and expects continued revenue growth for the full fiscal year. Additionally, it aims to reach adjusted EBITDA breakeven by the end of fiscal 2026. Despite these positives, some expenses, particularly in R&D and SG&A, have raised concerns about cost management going forward.

Twist Bioscience Reports Fiscal Second Quarter 2025 Financial Results - Record revenue of $92.8M in 2QFY25; Increase of 23% over $75.3M in 2QFY24, 9th consecutive quarter of sequential growth - - Gross margin of 49.6% in

Twist Bioscience reported strong financial results for its fiscal second quarter 2025, achieving record revenue of $92.8 million, a 23% increase compared to the previous year. The company also reached a gross margin of 49.6%, reflecting a significant improvement. In a strategic move, Twist announced the spin-out of its DNA Data Storage unit as Atlas Data Storage, aimed at accelerating growth and profitability. The company expects robust revenue guidance for the full fiscal year 2025, projecting revenues between $372 million and $379 million, along with a goal of achieving adjusted EBITDA breakeven by the end of fiscal 2026.

Feb 3, 2025

Twist Bioscience Reports Fiscal First Quarter 2025 Financial Results - Record revenue of $88.7M in 1QFY25 Increase of 24% over $71.5M in 1QFY24, 8th consecutive quarter of sequential growth - - Gross margin of 48.3% in 1

Twist Bioscience Corporation reported strong financial results for the first quarter of fiscal 2025, achieving record revenues of $88.7 million, marking a 24% increase year-over-year. This represents the eighth consecutive quarter of revenue growth, with improvements in gross margin rising to 48.3%. Despite reporting a net loss of $31.6 million, the company remains optimistic about its growth trajectory and has raised its full-year revenue guidance. The CEO expressed commitment to achieving adjusted EBITDA breakeven and sustained growth throughout 2025.

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2024 Financial Results - Record revenue of $313.0 million in Fiscal 2024 Increase of 28% over $245.1 million in Fiscal 2023 - - Record revenue of $84.7

Twist Bioscience Corporation has reported its fiscal fourth quarter and full year 2024 financial results, achieving record revenues of $313.0 million, a 28% growth from the previous year. The company continues to experience growth with a gross margin of 45.1% in Q4FY24, indicating improved profitability. Despite strong revenue figures, the company recorded a net loss of $208.7 million for the year. Looking forward, Twist expects revenues between $367 million and $377 million for fiscal 2025, highlighting continued optimism in their growth trajectory.

Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results - Record revenue of $81.5M in 3QFY24 , an increase of 28% over $63.7M in 3QFY23 - - Gross margin improved to 43.3% in 3QFY24 , increasing approximately

Twist Bioscience announced financial results for the third quarter of fiscal 2024, reporting a record revenue of $81.5 million, representing a 28% year-over-year increase. The gross margin also improved significantly, reaching 43.3%. The company has revised its fiscal 2024 revenue guidance upwards to approximately $310 million to $311 million, reflecting strong performance in its synthetic biology and next-generation sequencing product lines. However, the company continues to face notable net losses, which highlighted the financial challenges ahead despite positive revenue trends.

May 2, 2024

Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results - Record revenue of $75.3M in 2QFY24, an increase of 25% over $60.2M in 2QFY23 - - Orders increased to $93.2M in 2QFY24, growth of 45% over $64.2M in

Twist Bioscience reported strong financial performance for the second quarter of fiscal 2024, with a record revenue of $75.3 million, a 25% increase from the same period in the previous year. Orders also saw significant growth, totaling $93.2 million, up 45% year-over-year. The company improved its gross margin to 41% and updated its revenue guidance for the full fiscal year, anticipating revenues between $300 million and $304 million. However, biopharma revenue experienced a decline, raising concerns about certain segments of their business.

Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results - Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 - - Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23

Twist Bioscience reported a strong financial performance for the first quarter of fiscal 2024, achieving record revenues of $71.5 million, which is a 32% increase compared to the same quarter last year. Orders also saw growth, increasing to $77.5 million, driven by strong sales in synthetic biology and next-generation sequencing (NGS). The company has raised its revenue guidance for the full fiscal year to a range of $288 million to $293 million. However, they experienced a net loss of $43 million for the quarter, slightly more than the previous year's loss.

Jan 5, 2024

Twist Bioscience Appoints Adam Laponis as Chief Financial Officer SOUTH SAN FRANCISCO

Twist Bioscience Corporation has appointed Adam Laponis as the new Chief Financial Officer. Laponis brings a wealth of experience from various industries, including significant roles at Tesla and Eargo. His appointment comes at a crucial time as Twist aims for cash flow breakeven, focusing on profitability and growth. The company's proprietary technology for DNA synthesis is set to play a crucial role in various sectors, including healthcare and agriculture.

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results -- Record revenue of $245.1 million in Fiscal 2023 Increase of 20% over $203.6 million in Fiscal 2022 -- -- Orders increased to $

Twist Bioscience reported strong financial results for fiscal 2023, achieving a record revenue of $245.1 million, up 20% from the previous year. The company also saw a growth in total orders to $264 million, indicating strong demand for its synthetic DNA products. Looking ahead, Twist anticipates further revenue growth in fiscal 2024, with expected revenue in the range of $285 to $290 million. However, the company continues to report substantial net losses, highlighting ongoing challenges in cost management.

Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results -- Record revenue of $63.7M in 3QFY23 Increase of 14% over $56.1M in Fiscal 2022 - -- Orders increased 7% in 3QFY23 over fiscal 2022 to $63.8M -- SOUTH

Twist Bioscience Corporation reported record revenue of $63.7 million for the third quarter of fiscal 2023, marking a 14% increase over the previous year. Orders also rose by 7% to $63.8 million, reflecting growth driven by its core synthetic biology and next-generation sequencing businesses. Despite these financial gains, the company reported a net loss of $57.4 million and anticipates delays in reaching EBITDA breakeven for its biopharma segment. Looking ahead, Twist is optimistic about expanding its product offerings and customer base.

May 23, 2023

Twist Bioscience Appoints Robert Werner as Chief Accounting Officer

Twist Bioscience Corporation has appointed Robert Werner as Chief Accounting Officer, enhancing their leadership team with his extensive accounting experience in the biotech sector. Werner previously served as the Chief Accounting Officer at Invitae, where he oversaw significant revenue growth. Twist is focused on achieving adjusted EBITDA breakeven for its core business and biopharma operations by the end of fiscal Q4 2024, leveraging its innovative synthetic DNA technology to expand its market share and applications across various industries.

May 5, 2023

Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results - Record revenue of $60.2M in 2QFY23 up 25% over $48.1M in 2QFY22 - - Orders increased to $64.2M in 2QFY23 up 17% over 2QFY22 - -- Decisive Actions to

Twist Bioscience reported a successful fiscal second quarter for 2023, posting record revenue of $60.2 million, representing a 25% increase compared to the same quarter last year. Orders also experienced growth, reaching $64.2 million, as the company focuses on its Biopharma Solutions offering to enhance antibody discovery. However, the company is taking decisive steps towards profitability, which includes a 25% reduction in workforce and a withdrawal of its previous financial guidance for fiscal year 2024. Despite these challenges, the ongoing expansion into new business areas suggests potential for future growth.

Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results - Revenue of $54.2M in 1QFY23 increased 29% over $42.0M in 1QFY22 - - Orders increased to $64.7M in 1QFY23, an increase of 30% over 1QFY22 - SOUTH SAN

Twist Bioscience reported strong financial results for the first quarter of fiscal 2023, recording a 29% revenue increase to $54.2 million and a 30% rise in orders to $64.7 million compared to the same period last year. The company highlighted robust growth across its SynBio, NGS, and biopharma segments as it expands its customer base and capabilities. Despite the positive revenue performance, TWST reported a net loss of $41.8 million and an ongoing focus on capital efficiency and cost management for future growth.

Nov 18, 2022

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results -- Record revenue of $203.6 million in Fiscal 2022 Increase of 54% over $132.3 million in Fiscal 2021 - -- Orders increased to $2

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results -- Record revenue of $203.6 million in Fiscal 2022 Increase of 54% over $132.3 million in Fiscal 2021 - -- Orders increased to $226 million in Fiscal 2022 Increase of 42% over $160 millio

Nov 15, 2022

▼ -19.9%on this news· ran to -35% by day 3shared move

Twist Bioscience Addresses Misleading Short-Seller Report Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. Eastern Time

Twist Bioscience Addresses Misleading Short-Seller Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif. - November 15, 2022 - Twist Bioscience Corpora

Twist Bioscience Promotes Patrick Finn, Ph.D., to President and Chief Operating Officer Dr. Finn previously served as Twist's chief commercial officer

Bioscience Promotes Patrick Finn, Ph.D., to President and Chief Operating Officer Dr. Finn previously served as Twist's chief commercial officer SOUTH SAN FRANCISCO, Calif. - October 26, 2022 - Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succe

Twist Bioscience Reports Fiscal Third Quarter 2022 Financial Results -- Record revenue of $56.1M in 3QFY22 Increase of 60% over $35.0M in Fiscal 2021 - -- Orders increased 53% in 3QFY22 over fiscal 2021 to $59.7M -- - In

Twist Bioscience Reports Fiscal Third Quarter 2022 Financial Results -- Record revenue of $56.1M in 3QFY22 Increase of 60% over $35.0M in Fiscal 2021 - -- Orders increased 53% in 3QFY22 over fiscal 2021 to $59.7M -- - Increases revenue guidance to $203 million for full year fi

Twist Bioscience Reports Second Quarter 2022 Financial Results -- Record revenue of $48.1M in 2QFY22; Increase of 54% over $31.2M in Fiscal 2021 - -- Orders Increased 32% in 2QFY22 over Fiscal 2021 to $55.0M -- SOUTH SAN

Twist Bioscience Reports Second Quarter 2022 -- Record revenue of $48.1M in 2QFY22; Increase of 54% over $31.2M in Fiscal 2021 - -- Orders Increased 32% in 2QFY22 over Fiscal 2021 SOUTH SAN FRANCISCO, Calif. -- (May 5, 2022) - Twist Bioscience Corporation (NASDAQ: TWST), a c

Apr 21, 2022

▼ -10.8%on this news· ran to -21% by day 3

Twist Bioscience Announces Promotions and Changes to Executive Leadership Team

Twist Bioscience Announces Promotions and Changes to Executive Leadership Team SOUTH SAN FRANCISCO, CA - April 21, 2022 - Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon

Feb 4, 2022